1. Home
  2. CRSP vs COLD Comparison

CRSP vs COLD Comparison

Compare CRSP & COLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • COLD
  • Stock Information
  • Founded
  • CRSP 2013
  • COLD 1903
  • Country
  • CRSP Switzerland
  • COLD United States
  • Employees
  • CRSP N/A
  • COLD N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • COLD Real Estate Investment Trusts
  • Sector
  • CRSP Health Care
  • COLD Real Estate
  • Exchange
  • CRSP Nasdaq
  • COLD Nasdaq
  • Market Cap
  • CRSP 4.9B
  • COLD 4.8B
  • IPO Year
  • CRSP 2016
  • COLD 2018
  • Fundamental
  • Price
  • CRSP $57.68
  • COLD $16.15
  • Analyst Decision
  • CRSP Buy
  • COLD Buy
  • Analyst Count
  • CRSP 16
  • COLD 12
  • Target Price
  • CRSP $70.73
  • COLD $24.50
  • AVG Volume (30 Days)
  • CRSP 3.7M
  • COLD 2.9M
  • Earning Date
  • CRSP 08-04-2025
  • COLD 08-07-2025
  • Dividend Yield
  • CRSP N/A
  • COLD 5.70%
  • EPS Growth
  • CRSP N/A
  • COLD N/A
  • EPS
  • CRSP N/A
  • COLD N/A
  • Revenue
  • CRSP $37,675,000.00
  • COLD $2,626,425,000.00
  • Revenue This Year
  • CRSP $28.31
  • COLD $2.48
  • Revenue Next Year
  • CRSP $268.05
  • COLD $5.39
  • P/E Ratio
  • CRSP N/A
  • COLD N/A
  • Revenue Growth
  • CRSP N/A
  • COLD N/A
  • 52 Week Low
  • CRSP $30.04
  • COLD $16.01
  • 52 Week High
  • CRSP $71.13
  • COLD $30.45
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 52.32
  • COLD 42.98
  • Support Level
  • CRSP $61.13
  • COLD $16.08
  • Resistance Level
  • CRSP $69.58
  • COLD $17.12
  • Average True Range (ATR)
  • CRSP 3.89
  • COLD 0.44
  • MACD
  • CRSP -0.71
  • COLD 0.02
  • Stochastic Oscillator
  • CRSP 28.46
  • COLD 13.39

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About COLD Americold Realty Trust Inc.

Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 239 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.

Share on Social Networks: